Nano-X Imaging Ltd. Form 6-K Summary
Business Context and Reporting Period
Nano-X Imaging Ltd. filed this Form 6-K for September 2022. The filing reports a regulatory submission related to the company’s Nanox.ARC medical imaging system.
Material Event
On September 26, 2022, the company submitted a 510(k) premarket notification to the U.S. Food and Drug Administration as part of its 510(k) application process for the Nanox.ARC, a multi-source 3D digital tomosynthesis system.
The Nanox.ARC is described as a tomographic, solid-state X-ray system intended to capture tomographic slices of the human body from a single tomographic sweep.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial information.
Outlook, Risks, and Unusual Items
FDA clearance was not reported in this filing. The 510(k) submission is subject to FDA review, and the filing does not provide a review timeline, probability of clearance, commercial launch timing, or related financial impact.
Investor Verification Points
- Verify the status and outcome of the FDA 510(k) review for the Nanox.ARC.
- Assess any additional regulatory, technical, or clinical requirements imposed by the FDA.
- Review subsequent filings for commercialization timing, deployment plans, revenue generation, and funding needs.
- Note that this filing contains no updated financial results or guidance.
The report was signed on September 28, 2022, by Ran Daniel, Chief Financial Officer. Its information was incorporated by reference into the company’s Form S-8 registration statement, File No. 333-248322.